As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals, Inc. ZYNE. The stock has moved higher by 91.4% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider ZYNEâs recent earnings estimate revision activity. From this look, the companyâs future is quite favorable; as ZYNE has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isnât the top for the in-focus company. You can see the complete list of todayâs Zacks #1 Rank stocks here.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, â7 Things You Can Do Now to Retire a Multimillionaire.â
Click to get it free >>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
report
Zynerba Pharmaceuticals,
Inc. (ZYNE) : Free Stock Analysis Report
To read this article on
Zacks.com click here.
Zacks Investment Research